Securities Fraud Investigation Into Sionna Therapeutics, Inc. (SION) Continues – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm

Glancy Prongay Wolke & Rotter LLP is investigating Sionna Therapeutics for potential securities law violations following the company's announcement of a primary endpoint miss in its PreciSION CF Phase 2a trial on August 10, 2026. The news triggered a 91.2% stock price decline, falling from approximately $46.64 to $4.10 per share, prompting a class action lawsuit on behalf of affected shareholders.